Richard D Antrobus
Overview
Explore the profile of Richard D Antrobus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swadling L, Capone S, Antrobus R, Brown A, Richardson R, Newell E, et al.
Sci Transl Med
. 2014 Nov;
6(261):261ra153.
PMID: 25378645
A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV infects millions of people worldwide and is a leading cause of liver cirrhosis and hepatocellular cancer....
2.
Davenport E, Antrobus R, Lillie P, Gilbert S, Knight J
J Mol Med (Berl)
. 2014 Oct;
93(1):105-14.
PMID: 25345603
Unlabelled: Despite increases in vaccination coverage, reductions in influenza-related mortality have not been observed. Better vaccines are therefore required and influenza challenge studies can be used to test the efficacy...
3.
Satti I, Meyer J, Harris S, Manjaly Thomas Z, Griffiths K, Antrobus R, et al.
Lancet Infect Dis
. 2014 Aug;
14(10):939-46.
PMID: 25151225
Background: Intradermal MVA85A, a candidate vaccine against tuberculosis, induces high amounts of Ag85A-specific CD4 T cells in adults who have already received the BCG vaccine, but aerosol delivery of this...
4.
Antrobus R, Coughlan L, Berthoud T, Dicks M, Hill A, Lambe T, et al.
Mol Ther
. 2013 Dec;
22(3):668-674.
PMID: 24374965
Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian...
5.
Antrobus R, Berthoud T, Mullarkey C, Hoschler K, Coughlan L, Zambon M, et al.
Mol Ther
. 2013 Jul;
22(1):233-8.
PMID: 23831594
Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory...
6.
Antrobus R, Lillie P, Berthoud T, Spencer A, McLaren J, Ladell K, et al.
PLoS One
. 2012 Nov;
7(10):e48322.
PMID: 23118984
Background: Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost...
7.
Sheehy S, Duncan C, Elias S, Choudhary P, Biswas S, Halstead F, et al.
Mol Ther
. 2012 Oct;
20(12):2355-68.
PMID: 23089736
The induction of cellular immunity, in conjunction with antibodies, may be essential for vaccines to protect against blood-stage infection with the human malaria parasite Plasmodium falciparum. We have shown that...
8.
Lambe T, Spencer A, Mullarkey C, Antrobus R, Yu L, de Whalley P, et al.
Pediatr Infect Dis J
. 2012 Apr;
31(6):e86-91.
PMID: 22466328
Background: During seasonal influenza epidemics, 5-15% of the population are affected with an illness having a nontrivial mortality, morbidity and economic burden. Inactivated influenza vaccines are routinely used to prevent...
9.
Antrobus R, Khan N, Hislop A, Montamat-Sicotte D, Garner L, Rickinson A, et al.
J Infect Dis
. 2005 May;
191(11):1842-53.
PMID: 15871117
Leukocyte immunoglobulin-like receptor-1 (LIR-1) is an inhibitory receptor that negatively regulates T cell effector functions after interaction with host class I major histocompatibility complex molecules and, additionally, binds to UL18,...